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In advanced breast cancers, TP53 mutation is highly predictive of complete response to high-dose epirubicin/cyclophosphamide
chemotherapy. In these tumours with an altered control of genomic stability, accumulation of chemotherapy-induced genetic
alterations may contribute to cell death and account for complete response. To explore the effects of chemotherapy on stability of
the tumour genome, allelic profiles were obtained from microdissected tumour samples before and after chemotherapy in 29
unresponsive breast cancers (9 with TP53 mutation). Ninety-four per cent allelic profiles remained unchanged after treatment.
Interestingly, 11 profiles (6%) showed important changes after treatment; allelic imbalances significantly increased (four cases) or
decreased (seven cases) after chemotherapy in three distinct experiments, two of which using laser microdissected tumour cells.
These genetic changes were not linked to the TP53 status, but one tumour showed complete disappearance of TP53-mutated cells in
the residual tumour after treatment. Altogether, these observations carry important implications for the clonal evolution of breast
cancers treated with DNA-damaging agents, as they point both to the importance of tumour heterogeneity and chemotherapy-
driven selection of subclones.
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Breast cancers are a heterogeneous group of tumours. Whereas
most advanced breast cancer patients receive neoadjuvant
chemotherapy, less than 20% of them will fully benefit from this
type of treatment and reach complete pathological response, which
is closely linked with longer survival (Bertheau et al, 2005;
Kaufmann et al, 2005). The identification of predictive markers of
response to chemotherapy is therefore a critical challenge for
advanced breast cancer patients.
In previous studies (Bertheau et al, 2002, 2007), we have shown
in non-inflammatory locally advanced breast cancers that TP53
mutations are highly predictive of complete pathological response
to high-dose epirubicin/cyclophosphamide chemotherapy. TP53 is
known to control genomic integrity (Vogelstein et al, 2000), and is
induced by cytotoxic drugs (Lowe et al, 1993; Bunz et al, 1999),
whereas its potential role as a prognostic and a predictive marker
in cancer patients remains controversial (Vousden and Prives,
2005; Berns, 2006). We hypothesised that breast tumours with
TP53 mutations could accumulate genetic alterations leading to
complete tumour response through mitotic catastrophes and
tumour cell death (Huang et al, 2005). Whereas obviously, we
cannot explore the genome of tumours that underwent complete
response, those that were not eradicated can be analysed. Note that
we have previously shown that TP53 mutant tumours that did not
undergo complete remissions have a worse prognosis than the
other groups (Bertheau et al, 2007). This might be caused by
chemotherapy-induced additional genetic changes that favour
progression.
To test this hypothesis, we further explored the effects of
chemotherapy on the tumour genome. Early tumour genetic
changes after chemotherapy have been poorly studied in patients.
We analysed here, in 29 locally advanced breast cancers, the allelic
profiles obtained with ten polymorphic microsatellite markers
known to be often involved in breast carcinoma (Bertheau et al,
2001). Allelic profiles obtained after chemotherapy were compared
to those obtained before, using laser-microdissected surgical
specimen.
PATIENTS AND METHODS
Patients and tumours
Among 80 non-inflammatory locally advanced breast cancers
treated in a single institution from 1997 to 2001 with first-line
chemotherapy and already studied for their TP53 status and
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patients who fulfilled all the following criteria: patient informed of
the study according to our Institutional Review Board recommen-
dations; identical treatment (6 cycles of a dose–dense regimen
associating 75mgm
 2 epirubicin and 1200mgm
 2 cyclopho-
sphamide, given every 14 days with G-CSF support in case of
febrile neutropenia; Cottu et al, 1999); and incomplete pathological
response to treatment. The patients were women aged 23 to 87
(median age 43). Patients and tumours characteristics are given in
Table 1. TNM tumour stages are given according to the WHO
criteria (Sobin, 2002) and tumour grades are given according to
the modified Scarff Bloom and Richardson system (Elston and
Ellis, 1991). ESR1 and ERBB2 status were determined with
immunohistochemistry (primary antibodies, respectively, clone
6F11 and clone CB11, Novocastra, Newcastle, UK). All patients
underwent an initial open incisional biopsy, followed by chemo-
therapy and, three months after diagnosis, mastectomy and
axillary lymph node dissection were performed. Only tumours
with at least 5000 remaining cells on the mastectomy specimen
tissue sections were included in the analysis. Three different
categories of incomplete pathological response were individualised
according to a methodology previously validated (Bertheau et al,
2005): tumours with post-treatment cellular density less than 50%
compared to pre-treatment tumours defined ‘major pathological
response’, tumours with post-treatment cellular density only
slightly decreased, but with post-treatment cellular alterations
defined ‘minor pathological response’, whereas tumours that
remained unchanged after treatment defined ‘absence of response’.
TP53 typing
After tumour RNA extraction (Chomczynski and Sacchi, 1987),
TP53 status was determined by the yeast functional assay (Flaman
et al, 1995; Waridel et al, 1997). Tumours were considered TP53
mutant when (i) more than 15% of the yeast colonies were red and
(ii) analysis using the split versions of the test could identify the
defect in the 50 or 30 part of the gene, confirming the initial
determination and (iii) sequence analysis from mutant yeast
colonies could identify an unambiguous genetic defect (mutation,
deletion, splicing defectsy).
We determined the TP53 status with the yeast functional assay
in all 29 tumours before and after chemotherapy, whenever
sufficient frozen material was available for RNA extraction (18
tumours).
For the nine cases with TP53 mutation before treatment, frozen
tumour tissue was available after treatment in six cases and used to
perform the yeast functional test as well as TP53 gene sequencing.
For the other three mutated cases, we tried to use formalin-fixed
paraffin-embedded tissue, but failed to obtain good enough RNA
to perform the yeast functional assay or long enough DNA
fragments (4300bp) to perform gene sequencing.
For all nine mutated cases, TP53 immunostainings on paraffin-
embedded samples were obtained before and after treatment using
DO-7 monoclonal mouse anti-human antibody (Dako, Trappes,
France), diluted 1/50 in an automated immunostainer (Ventana
Medical Systems SA, Illkirch, France). The percentage of stained
cells (nuclear staining) was noted.
Laser-microdissection and pressure catapulting (LMPC)
Using a PALM Microbeam/Olympus system, LMPC was performed
on all 29 tumours before and after chemotherapy: 7mm thick
paraffin sections were spread on membrane-coated slides and
stained with H&E (Figure 1A). A pulsed UV-A nitrogen laser
(337nm) was used to cut and catapult small tissue fragments
Table 1 Clinicopathological data for the 29 patients
n (%)
Absence of
response
Minor
response
Major
response
Age
p50 22 (76) 3 14 5
450 7 (24) 1 3 3
Tumour stage
IIa 1 (3) — — 1
Ilb 3 (10) 1 1 1
IIIa 13 (45) 1 9 3
IIIb 8 (28) 1 6 1
IV 4 (14) 1 1 2
Histological tumour type
Ductal 25 (86) 2 16 7
Lobular 3 (10) 1 1 1
Mucinous 1 (4) 1 — —
Tumour grade
2 14 (48) 2 11 1
3 15 (52) 2 6 7
ESR1
Neg 8 (28) 2 1 5
Pos 21 (72) 2 16 3
ERBB2
Neg 23 (79) 3 16 4
Pos 6 (21) 1 1 4
TP53 status
Not
mutated
20 (69) 3 14 3
Mutated 9 (31) 1 3 5
Total 29 4 17 8
n, number of patients; ESR1, oestrogen receptor alpha.
Figure 1 (A) Laser-microdissection of breast carcinoma paraffin sections stained with H&E. The left panels show the selected areas (surrounded by a
black line) before microdissection and the right panels show the same areas after microdissection. Tumour cell density is much lower after chemotherapy
(lower panels). (B) Examples of unchanged profiles in two patients: retention of heterozygosity (left panels) or loss of heterozygosity (right panels) before
and after chemotherapy. (C and D) Examples of decreased AI in two patients. (C) For patient 7 marker D8S261, LOH is present before chemotherapy with
complete allelic loss on microdissected tumour (left panel) and important AI on not microdissected tumour (right panel). After chemotherapy, AI is strongly
reduced with both methods (lower panels). (D) For patient 3 marker D7S490, LOH is present before chemotherapy on microdissected tumour (left upper
panel) and LOH has disappeared after chemotherapy (left lower panel). Use of not microdissected tissue is not conclusive since tumour cells are
contaminated with numerous inflammatory cells (inset: tumour cells (T), inflammatory cells (Inf), necrosis (Nec)). (E and F) Examples of increased AI in two
patients. (E) For patient 32 marker D11S1356, there is no AI before chemotherapy with both microdissected and not microdissected tumours (upper
panels), whereas complete LOH is present after chemotherapy with microdissected tumour (lower left panel). Use of whole tumour tissue after
chemotherapy (lower right panel) is not conclusive (does not reach -50%), as tumour cells are contaminated with inflammatory cells (inset: tumour cells (T),
inflammatory cells (Inf)). (F) For patient 39 marker D16S496, LOH is present on the short allele before chemotherapy and on the long allele after
chemotherapy with microdissected tumour (left panels). Profiles with whole tumour tissue (right panels) are close. For all allelic profiles, normal DNA
profiles are shown in black (alleles N1 and N2), tumour DNA profiles are shown in colour (blue or green) (alleles T1 and T2). x-axis shows allelic size in base
pairs, y-axis shows fluorescence intensity.
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sdirectly into the buffer-containing cap of a microfuge tube. For
each tumour, at least 5000 cell sections obtained in several tumour
areas were lysed in 30ml of buffer (50mM Tris-HCl (pH 7.5), 1mM
EDTA, 0.5% Tween 20, 0.2mgml
 1 proteinase K). After an
incubation of 24–48h at 561C, proteinase K was inactivated at
951C for 10min. No further DNA extraction was performed before
PCR analysis for these microdissected samples (Bertheau et al,
2001).
Decreased allelic imbalances
Increased allelic imbalances
Before chemotherapy
After chemotherapy
Unchanged profiles
Laser microdissection 
A
CD
EF
B
Patient 32, D7S490, after chemotherapy
Patient 32, D7S490, before chemotherapy
Microdissected
Microdissected
Patient 6, D8S261, before chemotherapy
Patient 6, D8S261, after chemotherapy
Microdissected
Microdissected
N1
N2
T1
T2
T1
N1
N2
T2  (–100%)
N1
N2
T1
T2
N1
N2
T1
T2 ( –79%)
-5000
-2500
-5000
-2500
- 2000
- 1000
- 2000
- 1000
Patient 39, D16S496, before chemotherapy
Patient 39, D16S496, after chemotherapy
Microdissected
Patient 32, D11S1356, after chemotherapy
Patient 32, D11S1356, before chemotherapy
Microdissected
Microdissected
Patient 32, D11S1356, before chemotherapy
Patient 32, D11S1356, after chemotherapy
Inf T
Not microdissected
Not microdissected
Microdissected
Patient 39, D16S496, before chemotherapy
Patient 39, D16S496, after chemotherapy
Not
microdissected
Not microdissected
N1
N2
T1 (–24%)
T2
N1
N2
T1
T2 (–62%)
N1
N2
T1 (–80%)
N1
N2
T1
T2 (–100%)
N1 N2
T1
T2 (–35%)
N1
N2
T1
T2 (–42%)
N1
N2
T1
T2 (–15%)
N1 N2
T1
T2 (–100%)
T2
- 2000
- 1000
- 3000
- 1500
- 5000
- 2500
- 7000
- 3500
- 1000
- 500
- 2000
- 1000
- 500
- 250
- 5000
- 2500
Microdissected
Patient 3, D7S490, before chemotherapy
Patient 3, D7S490, after chemotherapy
Not microdissected
Not microdissected
Patient 3, D7S490, before chemotherapy
Patient 3, D7S490, after chemotherapy
Microdissected
T
Inf
Nec
Patient 7, D8S261, before chemotherapy
Patient 7, D8S261, after chemotherapy
Not microdissected
Not microdissected
Patient 7, D8S261,before chemotherapy
Patient 7, D8S261, after chemotherapy
Microdissected
Microdissected
N1
N2
T1
T2 (–100%) N1 N2
T1
T2 (–70%)
N1
N2
T1 T2 (–15%)
N1
N2
T1
T2 (–67%)
N1 N2
T1
T2 (–35%) 
N1
N2
T1
T2 (–9%)
N1
N2
T1 T2 (–1%)
N1
N2
T1 T2 (–1%)
5000
5000
2500
2500
7000
- 3500
- 6000
- 3000
- 7000
- 3500
- 3000
- 1500
- 4000
- 2000
- 7000
- 3500
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Control allelic profiles were obtained with DNA extracted from
blood cells: after cell lysis and proteinase K degradation, DNA was
obtained with phenol chloroform extraction followed by DNA
precipitation with ethanol and solved in TE buffer (Tris 10mM (pH
7.5), EDTA 1mM) (Muniz et al, 1994).
Tumours that showed post-treatment allelic changes with
microdissected samples (see Results) were also analysed with
DNA extracted from frozen whole tumour tissue. Briefly, frozen
tumour sections were immersed in a buffer containing 8 M urea,
0.3 M NaCl, 10mM EDTA, 2% SDS and 10mM Tris-HCL, pH 7.5,
and then submitted to phenol chloroform DNA extraction.
PCR
For microdissected cells, a volume of lysis buffer accounting for
500 cells was added in each PCR vial. For DNA extracted from
blood cells, 10ng DNA was used for each PCR. The following 10
microsatellite dinucleotide repeats were used (Table 2): D3S1573;
D7S490; D8S1820; D8S261; D11S860; D11S1356; D13S171;
D16S496; IGP53; and D17S855. The PCR mix contained 1U Taq
Gold (Applied Biosystems, Foster City, CA, USA), 2.5–4mM
MgCl2, 0.2mM dNTP, 0.2mM labelled forward primers (NEDt for
normal, FAM (6-carboxyfluorescein) or VICt for tumour) and
0.2mM non-labelled reverse primers. The PCR final volume was
20ml. Thirty-five cycles of PCR were performed.
After denaturation, the PCR products were run on ABI
PRISM 310 Genetic Analyzer. The analysis of the migration
data were performed with Genescan 3.1 software (Applied
Biosystems).
Allelic profiles analysis
Fluorescent allelic ratios obtained from microdissected tumour
tissue were compared with fluorescent allelic ratios obtained from
control DNA, allowing the measurement of allelic imbalances (AI).
Loss of heterozygosity (LOH) was defined as AI greater than 50%
for one tumour allele.
AI observed after chemotherapy were then compared to AI
observed before chemotherapy, showing locus with unchanged AI,
decreased AI or increased AI. Decreased or increased AI were
considered significant only when allelic peak heights differed by at
least 50%. This threshold was chosen to minimize the risk of false-
positive results induced by PCR variations. All these significant
pre-post-treatment differences were verified with a second round
of PCR performed with microdissected tissue and a third round of
PCR performed with frozen whole tumour DNA.
RESULTS
Allelic profiles before chemotherapy
Among a total of 290 ‘before chemotherapy’ PCR (10 markers
performed in 29 tumours), 63 allelic profiles were homozygote
(non-informative) and 15 PCR could not be analysed due to
technical issues. The rates of informativity for these markers were
similar to those expected from databases (Tables 2 and 3). The 212
informative profiles revealed 87 (41%) LOH and 125 (59%)
retentions of heterozygosity. Rates of LOH at each locus were
similar to those observed in the literature in the corresponding
chromosomal regions (Kerangueven et al, 1997; Braga et al, 1999;
Katsama et al, 2000; Osborne and Hamshere, 2000; Shen et al,
2000; Hirano et al, 2001; Miyakis and Spandidos, 2002; Wang et al,
2004; Mao et al, 2005).
Allelic profiles after chemotherapy
Among a total of 290 ‘after chemotherapy’ PCR (29 tumours, 10
markers), 63 allelic profiles were homozygote (non-informative)
and 24 PCR could not be analysed due to technical issues. The 203
informative profiles revealed 78 (38%) LOH and 125 (62%)
retentions of heterozygosity. (Tables 2 and 3)
Comparison of allelic profiles before and after
chemotherapy
Altogether, 191 pairs of PCR were informative and analysable
before and after chemotherapy. In 180 pairs (94%), allelic profiles
before and after chemotherapy were not different (Figure 1B;
Table 3, green cells). However, in 11 pairs, pre- and post-
chemotherapy profiles were significantly different. In seven pairs
(4%), AI observed before chemotherapy had significantly
decreased after chemotherapy (Figure 1C and D; Table 3, blue
cells). In two pairs (1%), almost normal profiles observed before
chemotherapy were clearly imbalanced after chemotherapy
(Figure 1E; Table 3, orange cells). In 2 pairs (1%), AI observed
for one allele before chemotherapy was found for the other allele
after chemotherapy (Figure 1F; Table 3, orange* cells).
Table 2 Characteristics of the ten microsatellites analysed: results of the 29 patients are compared to the literature data
Locus
Chromosomal
region
Length of PCR
product
% of LOH in the
chromosomal region in
breast tumours in the
literature
LOH at the defined locus
in informative cases
before chemotherapy in
this study
LOH at the defined locus
in informative cases
after chemotherapy in
this study
D3S1573 3p21.31 136–154 21–41% (Braga et al, 1999) 6/18 (33%) 7/19 (37%)
D7S490 7q31.32 92–106 11% (Mao et al, 2005) 5/26 (19%) 5/25 (20%)
D8S1820 8p21.1 103–117 29% (Wang et al, 2004) 10/20 (50%) 9/19 (47%)
D8S261 8p22 128–144 52% (Hirano et al, 2001);
26% (Wang et al, 2004)
13/23 (57%) 10/24 (42%)
D11S860 11p15 154–196 28% (Hirano et al, 2001) 5/14 (36%) 5/11 (45%)
D11S1356 11q23.3 193–213 47% (Hirano et al, 2001);
50% (Wang et al, 2004)
14/23 (61%) 11/21(52%)
D13S171 13q13 227–231 34% (Miyakis and Spandidos, 2002) 9/18 (50%) 6/18 (33%)
D16S496 16q22.1 209–226 42% (Shen et al, 2000) 6/23 (26%) 10/22 (45%)
IGP53 17p13.1 97–138 51% (Hirano et al, 2001);
56% (Wang et al, 2004)
9/23 (39%) 6/20 (30%)
D17S855 17q21.31 143–155 34% (Hirano et al, 2001);
43% (Mao et al, 2005)
12/24 (50%) 10/24 (42%)
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sTable 3 Allelic profiles before and after chemotherapy in 29 tumours with or without TP53 mutation
3
ESR1, oestrogen receptor alpha; H, homozygous patients; L, long allele; NA, not analysable; pR, pathological response (A absence of response, m minor response, M major response); S, short allele. Allelic imbalances (AI) are given by
the percentage of allelic decrease. Comparison between post- and pre-chemotherapy profiles (column ‘after vs before’) is shown as green boxes (unchanged profiles), orange boxes (increased AI over 50%), blue boxes (decreased AI
over 50%).
aAllelic imbalance on one allele before chemotherapy and on the other allele after chemotherapy.
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Genetics and GenomicsFor these 11 important changes detected after chemotherapy,
we reproduced once the analysis with microdissected samples. A
further analysis with non-microdissected extracted DNA showed
very close results (Figure 1C and F) in five pairs, and non-
conclusive results (Figure 1D and E) in the other six pairs.
Allelic profiles and TP53 status
The overall rates of LOH at all loci were similar in tumours with or
without TP53 mutations, before (47 and 38%, respectively) or after
treatment (41 and 37%, respectively).
LOH at the TP53 intragenic IGP53 locus before treatment was
observed in 4 out of these 9 tumours with TP53 mutation (44%)
and in 5 out of 20 tumours without TP53 mutation (20%). Eighteen
tumours had sufficient post-treatment frozen material to allow
analysis with the yeast functional assay after chemotherapy.
Among them, all 12 tumours that did not bear TP53 mutation
before treatment did not show post-treatment TP53 mutation.
Six out of nine tumours with TP53 mutation before treatment
had good quality post-treatment tissue available and have been
further analysed for post-treatment TP53 status (Table 4). Among
these six tumours, two still bore a mutation after treatment
(patients 3 and 12), whereas no mutation could be detected by the
functional test in four others patients (patients 7, 8, 9 and 11). For
these four patients with absence of detectable TP53-mutated cells
after treatment, note that three of them had either a dense
inflammatory stroma (patients 9 and 11) or a single small (2mm)
residual focus of tumour cells (patient 8).
Allelic profiles and clinicopathological data
The distribution of the 11 post-chemotherapy profile changes was
not linked to any other clinicopathological parameter (age, tumour
grade, tumour stage, ESR1 status, ERBB2 status and type of
incomplete pathological response) and was not linked to the pre-
treatment TP53 status of the tumours.
DISCUSSION
We found that genetic changes are detectable early after
chemotherapy in breast cancers.
All 29 patients had poor prognosis breast tumours treated with
the same dose–dense epirubicin/cyclophosphamide regimen. The
large amount of tumour tissue obtained before (open incisional
biopsy) and after (mastectomy) treatment allowed reliable assess-
ment of response to treatment. Obtaining such homogeneous
pre- and post-chemotherapy tissue samples is difficult and
explains why we could study only 29 patients.
Advanced breast cancers are often high grade with necrotic
areas, and become more heterogeneous after treatment, with
inflammatory infiltrate, oedema, fibrosis and necrosis. To over-
come tissue heterogeneity, we used laser tissue microdissection,
which allows a targeted sampling of tumour cells with very little
contamination. In this regard, 20/29 tumours in our study had at
least one allelic loss greater than 80%, indicating that tumour
tissue samples were made of almost pure tumour cells. Although
laser-microdissection is a highly efficient sampling method, it
yields limited amounts of tissue material, and we took special care
of sampling at least 5000 cells for each tumour. Indeed, allelic
profiling must take into account allelic dropout artefacts that are
artificial allelic imbalances occurring when DNA concentration is
too low (Coulet et al, 2000; Miller et al, 2002). Several tumour areas
were sampled in each tumour to obtain a full representativity of
the tumour cell population and to avoid the sampling of genetically
different subclones. In addition, all PCR showing important
differences between pre- and post-treatment allelic profiles were
confirmed with a second round of PCR using microdissected
material and a third PCR with non-microdissected tumour tissue.
The chemotherapeutic regimen used in this study contained
epirubicin and cyclophosphamide that are both well known for
their cytotoxic and mutagenic effects in vitro. Anthracyclins are
topoisomerase II inhibitors that induce DNA double-strand breaks
(Ferguson and Baguley, 1996). In animal or human cell cultures,
anthracyclins induce chromosomal alterations rather than muta-
tions (El-Mahdy Sayed Othman, 2000; Baumgartner et al, 2004),
often through homologous recombination mechanisms (Lehmann
et al, 2003). The altered cells then either engage their apoptotic
programme or accumulate genetic alterations (Morris et al, 1995).
Alkylating agents transfer alkyl groups to cellular constituents,
inducing DNA adducts as well as DNA crosslinking that may lead
to point mutations (Sanderson and Shield, 1996; Hunter et al,
2006). A recent study using microarray-based CGH on 21 breast
tumours before and after epirubicin/cyclophosphamide chemo-
therapy showed a significant acquired copy number gain on
11p15.2–11p15.5 after treatment (Pierga et al, 2007). In 30 patients
with breast cancers treated with alkylating agents, microsatellite
instability and LOH were found in peripheral blood mononuclear
cells, respectively, in 27 and in 6 patients (Fonseca et al, 2005),
illustrating how acute chemotherapy-induced DNA damage can
also affect normal cells.
In our study, at least two different mechanisms could explain the
increase of AI at 11p15 and 11q23.3 after chemotherapy: a pre-
existent undetectable small population of tumour cells bearing one
AI could have been selected by the treatment that would have
preferentially targeted the tumour cells without AI. Alternatively,
new AI could be directly induced by the treatment in a sufficient
number of tumour cells to become detectable through molecular
analyses. In this regard, changes induced by anthracyclins at the
Table 4 TP53 status before and after treatment in the nine TP53-mutated tumours
Patient
number TP53 gene status
a before treatment
TP53 gene status
a
after treatment
TP53 IHC before
treatment
TP53 IHC after
treatment
3 Mut 82% (Codon 175, R vs H) Mut 93% (Codon 175, R vs H) 30% 10%
12 Mut 23% (Codon 158, Insert - frameshift) Mut 30% (Codon 158, Insert - frameshift) Negatif Negatif
7 Mut 22% (Codon 144, Q vs STOP codon) WT Negatif Negatif
8 Mut 96% (Codon 220, Y vs C) WT 50% 10%
9 Mut 54% (Codon 273, R vs H) WT 20% 20%
11 Mut 20% Codon 317, Q vs STOP codon) WT Negatif Negatif
6 Mut 63% (Codon 248, R vs W) NA 80% 50%
10 Mut 30% (Codons 131 to 133,
deletion- frameshift)
NA Negatif Negatif
20 Mut 62% (Codon 193, H vs R) NA 40% Negatif
IHC, immunohistochemistry; Mut, mutated; NA, not available; WT, wild type.
aPer cent of mutated yeast colonies (mutation type).
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and Travis, 2005). We also observed in two tumours, at D13S171
(13q13.1) (patient 6) and D16S496 (16q22.1) (patient 39),
imbalance on one allele before chemotherapy followed by
imbalance on the other allele after chemotherapy. These ‘inversed
profiles’ could be explained by selection of a minor subclone
bearing one allelic loss through a preferential effect of the drug on
a major subclone bearing loss of the other allele. In seven PCR (six
tumours, five markers: D7S490 (7q31.32), D8S261 (8p22),
D11S1356 (11q23.3), D13S171 (13q13.1) and IGP53 (17p13.1), AI
present before treatment strongly decreased after treatment,
leading to almost normal allelic profiles in five cases. Contamina-
tion by non-tumour cells may hide AI in tumour cells, but we
purposely used laser microdissection to prevent this bias. The
most likely explanation for these ‘improvements’ is chemotherapy-
driven selection of tumour subclones without AI.
One purpose of our study was to determine whether post-
chemotherapy genetic abnormalities could occur at different rates
in TP53-mutated versus TP53-nonmutated breast tumours. TP53
mutations are observed in 20 to 30% of breast carcinomas and are
linked to poor prognosis (Turpin et al, 1999; Olivier et al, 2006).
Loss of TP53 function may result in increased genetic instability
with higher frequency of mutations, chromosomal abnormalities,
gene amplifications, LOH and abnormal chromosome segregation
(Fukasawa et al, 1996; Morris, 2002). Our study failed to
demonstrate strong link between the pre-treatment TP53 status
of the tumours and the occurrence of post-treatment genetic
events. Further investigations using xenografted human breast
tumours would allow sequential analyses of the genetic alterations
during chemotherapy-induced tumour regression. Yet in four
cases (patients 7, 8, 9 and 11), the TP53 mutation found before
chemotherapy was not found after (Table 4). This could indicate,
as in our previous observations, that the TP53-mutated cells were
targeted by the chemotherapy, especially in one case (patient 7)
that showed a low post-treatment stromal cell density as well as an
important decrease of the proportion of cells with TP53 LOH
(Table 3). The other three post-treatment tumours (patients 9, 11
and 8) had either a high stromal cell density (patients 9 and 11) or
consisted of a single small residual nodule (patient 8) that might
have impeded detection of the TP53 mutation in these non-
microdissected frozen samples. Immunohistochemistry showed
either negative stainings or a trend to a decrease in the proportion
of TP53-overexpressing cells after treatment, pointing to higher
chemosensitivity of TP53-mutated cells, even if TP53 immunohis-
tochemistry is a less reliable indicator of the TP53 gene status than
the yeast functional assay.
In this study, we demonstrate that genetic changes do occur
early after chemotherapy in breast carcinomas. The most likely
explanation for our observations is chemotherapy-driven selection
of tumour subclones: breast cancer tumour cells are well known to
be highly heterogeneous (Shipitsin et al, 2007) and those already
bearing genetic alterations may be more sensitive to chemotherapy
and enter apoptosis more rapidly than unaltered cells. Another
recent report also showed that such post-treatment changes do
exist but, as in our study, seem to be rare (Pierga et al, 2007).
Whether specific molecular abnormalities can facilitate or impede
response to therapy is a crucial issue in oncology (Tanner et al,
2006). However, exquisite chemosensitivity linked with specific
allelic losses in tumours has not been reported yet. The
disappearance of TP53-mutated cells after chemotherapy in one
case (patient 7) is clearly in favour of clonal selection. Yet,
whatever the mechanism, these treatment-induced events should
favour the emergence of therapy-resistant tumour subclones and
subsequent tumour recurrences.
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